DAIS Corp - Quarter Report: 2009 June (Form 10-Q)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q
þ
|
Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
|
|
For the quarterly period
ended June 30, 2009
|
||
¨
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
|
|
For the transition period
from __________ to
__________
|
Commission
File No. 333-152940
DAIS
ANALYTIC CORPORATION
(Exact
name of Registrant as specified in its charter)
New
York
|
14-1760865
|
|
(State
or other jurisdiction of incorporation or organization)
|
(IRS
Employer Identification No.)
|
11552
Prosperous Drive, Odessa, FL 33556
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (727) 375-8484
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Exchange Act during the preceding
12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements
for at least the past 90 days. Yes x No ¨
Indicate
by a check mark whether the registrant has submitted electronically and posted
on its corporate website, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes¨ No ¨
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting company. See
the definitions of “accelerated filer, large accelerated filer and smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨
|
Smaller
reporting company x
|
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes ¨ No x
There
were 19,080,037shares of the Registrant’s $0.01 par value common stock
outstanding as of August 13, 2009.
Dais
Analytic Corporation
INDEX
Page
|
|||||
No.
|
|||||
Part
I. Financial Information
|
|||||
|
|||||
Item
1.
|
Financial
Statements
|
3
|
|||
Balance
Sheets
June
30, 2009 (Unaudited) and December 31, 2008
|
3
|
||||
|
|||||
Statements
of Operations
Three
and six months ended June 30, 2009 and 2008
(Unaudited)
|
4
|
||||
Statements
of Stockholders’ Deficit
Six
months ended June 30, 2009 (Unaudited)
|
5
|
||||
Statements
of Cash Flows
Six
months ended June 30, 2009 and 2008
(Unaudited)
|
6
|
||||
Notes
to Financial Statements (Unaudited)
|
7 | ||||
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operation
|
16
|
|||
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
22
|
|||
Item
4T.
|
Controls
and Procedures
|
22
|
|||
Part
II. Other Information
|
22
|
||||
|
|
||||
Item
1.
|
Legal
Proceedings
|
22
|
|||
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
23
|
|
||
Item
3.
|
Default
Upon Senior Securities
|
23
|
|||
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
23
|
|||
Item
5.
|
Other
Information
|
23
|
|||
Item
6.
|
Exhibits
|
24
|
|||
Signatures
|
25
|
2
PART
I—FINANCIAL INFORMATION
Dais
Analytic Corporation
Balance
Sheets
June
30, 2009
|
December
31,
|
|||||||
(Unaudited)
|
2008
|
|||||||
Assets
|
||||||||
Current
assets:
|
||||||||
Cash
|
$ | 34,888 | $ | 26,867 | ||||
Accounts
receivable
|
273,564 | 188,970 | ||||||
Inventory
|
138,591 | 147,128 | ||||||
Loan
costs, net of accumulated amortization
|
— | 1,004 | ||||||
Prepaid
expenses and other current assets
|
57,032 | 31,181 | ||||||
Total
current assets
|
504,075 | 395,150 | ||||||
Property
and equipment, net of accumulated depreciation of $311,734 and $307,286
at June 30, 2009 and December 31, 2008,
respectively
|
22,486 | 26,933 | ||||||
Other
assets:
|
||||||||
Deposits
|
2,280 | 2,280 | ||||||
Patents,
net of accumulated amortization of $101,327 and $96,389 at June
30, 2009 and December 31, 2008, respectively
|
54,444 | 44,129 | ||||||
Total
other assets
|
56,724 | 46,409 | ||||||
$ | 583,285 | $ | 468,492 | |||||
Liabilities
and Stockholders’ Deficit
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable, including related party payables of $130,321 and $105,925 at
June
30, 2009 and December 31, 2008, respectively
|
$ | 558,847 | $ | 380,022 | ||||
Accrued
expenses, other
|
338,029 | 340,115 | ||||||
Accrued
compensation and related benefits
|
1,245,189 | 1,147,389 | ||||||
Current
portion of deferred revenue
|
84,145 | 84,145 | ||||||
Current
portion of notes payable, net of unamortized discount of $0 and
$30,137
at June 30, 2009 and December 31, 2008, respectively,
including related party payable
of $62,524 and $624 at June 30, 2009 and December 31, 2008,
respectively
|
2,087,524 | 2,245,488 | ||||||
Total
current liabilities
|
4,313,734 | 4,197,159 | ||||||
Long-term
liabilities:
|
||||||||
Long-term
portion of notes payable, net of unamortized discount of
$6,965
|
— | 675,000 | ||||||
Deferred
revenue, net of current portion
|
251,697 | 293,769 | ||||||
Total
long-term liabilities
|
251,697 | 968,769 | ||||||
Stockholders’
deficit:
|
||||||||
Series
A preferred stock; $.01 par value; 10,000,000 shares authorized; 0 shares
issued and
outstanding
|
||||||||
Common
stock; $.01 par value; 100,000,000 shares authorized; 18,773,969
and 12,162,398 shares issued; 18,516,756 and 11,905,185 shares
outstanding
at June 30, 2009 and December 31, 2008, respectively
|
187,740 | 121,624 | ||||||
Capital
in excess of par value
|
26,872,179 | 25,253,196 | ||||||
Prepaid
services paid for with common stock
|
— | (23,375 | ) | |||||
Accumulated
deficit
|
(29,769,953 | ) | (28,776,769 | ) | ||||
Treasury
stock at cost, 257,213
|
(1,272,112 | ) | (1,272,112 | ) | ||||
Total
stockholders’ deficit
|
(3,982,146 | ) | (4,697,436 | ) | ||||
$ | 583,285 | $ | 468,492 |
The
accompanying notes are an integral part of the financial
statements.
3
Dais
Analytic Corporation
Statements
of Operations
(Unaudited)
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Revenue:
|
||||||||||||||||
Sales
|
$ | 507,318 | $ | 263,043 | $ | 643,634 | $ | 455,517 | ||||||||
License
fees
|
21,035 | 21,035 | 42,072 | 42,072 | ||||||||||||
528,353 | 284,078 | 685,706 | 497,589 | |||||||||||||
Expenses:
|
||||||||||||||||
Cost
of goods sold
|
337,574 | 218,057 | 444,544 | 377,990 | ||||||||||||
Selling,
general and administrative
|
439,426 | 502,304 | 982,798 | 1,758,403 | ||||||||||||
777,000 | 720,361 | 1,427,342 | 2,136,393 | |||||||||||||
Loss
from operations
|
(248,647 | ) | (436,283 | ) | (741,636 | ) | (1,638,804 | ) | ||||||||
Other
expense (income):
|
||||||||||||||||
Interest
expense
|
95,353 | 831,435 | 251,585 | 1,690,655 | ||||||||||||
Interest
income
|
— | (5,526 | ) | (37 | ) | (16,282 | ) | |||||||||
95,353 | 825,909 | 251,548 | 1,674,373 | |||||||||||||
Net
loss
|
$ | (344,000 | ) | $ | (1,262,192 | ) | $ | (993,184 | ) | $ | (3,313,177 | ) | ||||
Net
loss per common share, basic and diluted
|
$ | (0.02 | ) | $ | (0.13 | ) | $ | (0.06 | ) | $ | (0.36 | ) | ||||
Weighted
average number of common shares, basic and diluted
|
17,821,497 | 9,470,517 | 15,600,875 | 9,208,487 |
4
Dais
Analytic Corporation
Statements
of Stockholders’ Deficit
For
the Six Months Ended June 30, 2009
Series A
Preferred Stock
|
Common Stock
|
|||||||||||||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital in Excess of
Par Value
|
Accumulated Deficit
|
Prepaid Services
Paid for with
Common Stock
|
Treasury Stock
|
Stockholders’
Deficit
|
||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||
Balance,
December 31, 2008
|
$ | - | $ | - | 12,162,398 | $ | 121,624 | $ | 25,253,196 | $ | (28,776,769 | ) | $ | (23,375 | ) | $ | (1,272,112 | ) | $ | (4,697,436 | ) | |||||||||||||||||||
Issuance
of common stock for conversion of notes payable and related accrued
interest (unaudited)
|
- | - | 5,129,648 | 51,297 | 974,634 | - | - | - | - | 1,025,931 | ||||||||||||||||||||||||||||||
Issuance
of common stock and warrant for services
(unaudited)
|
- | - | 208,846 | 2,088 | 67,657 | - | 23,375 | - | 93,120 | |||||||||||||||||||||||||||||||
Stock
compensation expense (unaudited)
|
- | - | - | - | 148,306 | - | - | - | - | 148,306 | ||||||||||||||||||||||||||||||
Issuance
of warrants for debt conversion (unaudited)
|
- | - | - | - | 110,117 | - | - | - | 110,117 | |||||||||||||||||||||||||||||||
Issuance
of common stock and warrants for cash (unaudited)
|
- | - | 1,273,077 | 12,731 | 318,269 | - | - | - | - | 331,000 | ||||||||||||||||||||||||||||||
Net
loss for the six months ended June 30, 2009 (unaudited)
|
-
|
- | - | - | - | - | (993,184 | ) | - | - | (993,184 | ) | ||||||||||||||||||||||||||||
Balance,
June 30, 2009 (unaudited)
|
$ | - | $ | - | 18,773,969 | $ | 187,740 | $ | 26,872,179 | $ | (29,769,953 | ) | - | $ | (1,272,112 | ) | $ | (3,982,146 | ) |
The
accompanying notes are an integral part of the financial
statements.
5
Dais
Analytic Corporation
Statements
of Cash Flows
(Unaudited)
Six
Months Ended June 30,
|
||||||||
2009
|
2008
|
|||||||
Operating
activities
|
||||||||
Net
loss
|
$ | (993,184 | ) | $ | (3,313,177 | ) | ||
Adjustments
to reconcile net loss to net cash used by operating
activities:
|
||||||||
Depreciation
and amortization
|
9,385 | 8,464 | ||||||
Amortization
of deferred loan costs
|
1,004 | 52,742 | ||||||
Amortization
of discount on convertible notes
|
144 | 772,165 | ||||||
Amortization
of the beneficial conversion feature on convertible notes
|
29,992 | 667,287 | ||||||
Write
off of deferred noncash offering costs
|
— | 55,000 | ||||||
Stock
based compensation
|
148,306 | 946,202 | ||||||
Issuance
of common stock for future services and amortization of common stock
issued for future services
|
65,395 | 2,125 | ||||||
Issuance
of common stock warrants for conversion of notes payable
|
110,117 | 43,111 | ||||||
Issuance
of options and warrants for services
|
27,726 | — | ||||||
Value
of beneficial conversion feature for conversion of notes payable and
related accrued interest
|
— | 21,708 | ||||||
(Increase)
decrease in:
|
||||||||
Accounts
receivable
|
(84,594 | ) | (187,874 | ) | ||||
Inventory
|
8,537 | (44,933 | ) | |||||
Prepaid
expenses and other current assets
|
(25,851 | ) | (5,832 | ) | ||||
Increase
(decrease) in:
|
||||||||
Accounts
payable and accrued expenses
|
277,669 | 69,615 | ||||||
Accrued
compensation and related benefits
|
97,800 | 21,876 | ||||||
Deferred
revenue
|
(42,072 | ) | (42,072 | ) | ||||
Net
cash used by operating activities
|
(369,626 | ) | (933,593 | ) | ||||
Investing
activities
|
||||||||
Purchase
of property and equipment
|
— | (14,647 | ) | |||||
Increase
in patents
|
(15,253 | ) | — | |||||
Net
cash used by investing activities
|
(15,253 | ) | (14,647 | ) | ||||
Financing
activities
|
||||||||
Proceeds
from issuance of notes payable
|
— | 500,000 | ||||||
Proceeds
of issuance of notes payable, related party
|
61,900 | — | ||||||
Proceeds
received from escrow
|
— | 1,000,000 | ||||||
Payments
on notes payable
|
— | (100,000 | ) | |||||
Payments
for loan costs
|
— | (34,000 | ) | |||||
Issuance
of common stock for cash
|
331,000 | — | ||||||
Net
cash provided by financing activities
|
392,900 | 1,366,000 | ||||||
Net
increase in cash
|
8,021 | 417,760 | ||||||
Cash,
beginning of period
|
26,867 | 504,232 | ||||||
Cash,
end of period
|
$ | 34,888 | $ | 921,992 | ||||
Cash
paid for interest
|
$ | 403 | $ | 10,100 |
Supplemental disclosures
of noncash investing and financing
activities:
During
the six months ended June 30, 2009, the Company issued 208,846 shares of common
stock valued at $69,745 for future services.
During
the six months ended June 30, 2009, the Company issued 5,129,648 shares of
common stock in conversion of $925,000 of notes payable and $100,930 of accrued
interest.
During
the six months ended June 30, 2008, the Company issued 240,000 shares of common
stock valued at $86,000 as payment for future services.
During
the six months ended June 30, 2008, the Company issued 439,293 shares of common
stock in conversion of $100,000 of notes payable and $8,540 of accrued
interest.
During
the six months ended June 30, 2008, the Company issued convertible notes payable
with a beneficial conversion feature of $245,106 and a discount equivalent to
the relative fair value of the accompanying warrants of $254,894.
The
accompanying notes are an integral part of the financial
statements.
6
Dais
Analytic Corporation
Notes
to Financial Statements
Three
and Six Months Ended June 30, 2009
(Unaudited)
1. Background
Information
Dais
Analytic Corporation (the “Company”), a New York corporation, has developed and
is commercializing applications using its nano-structure polymer technology. The
first commercial product is an energy recovery ventilator (“ERV”) (cores and
systems) for use in commercial Heating, Ventilating, and Air Conditioning (HVAC)
applications. In addition to direct sales, the Company licenses its
nano-structured polymer technology to strategic partners in the aforementioned
application and is in various stages of development with regard to other
applications employing its base technologies. The Company was
incorporated in April of 1993 with its corporate headquarters located in Odessa,
Florida.
2. Going
Concern
The
accompanying financial statements have been prepared assuming that the Company
will continue as a going concern. For the six months ended June 30,
2009, the Company incurred a net loss of $993,184. As of June 30,
2009, the Company has an accumulated deficit of $29,769,953, negative working
capital of $3,809,659 and a stockholder’s deficit of $3,982,146 and is in
default on notes in the aggregate principal amount of $1,450,000. In view
of these matters, there is substantial doubt that the Company will continue as a
going concern. The recoverability of recorded property and equipment,
intangible assets, and other asset amounts shown in the accompanying financial
statements is dependent upon the Company’s ability to continue as a going
concern and to achieve a level of profitability. The Company intends
on financing its future activities and its working capital needs largely from
the sale of public equity securities with some additional funding from other
traditional financing sources, including term notes and proceeds from
sub-licensing agreements until such time that funds provided by operations are
sufficient to fund working capital requirements. However, there can
be no assurance that the Company will be successful in its
efforts. The financial statements of the Company do not include any
adjustments relating to the recoverability and classification of recorded
assets, or the amounts and classifications of liabilities that might be
necessary should the Company be unable to continue as a going
concern.
3. Significant
Accounting Policies
In the
opinion of management, all adjustments consisting only of normal recurring
adjustments necessary for a fair statement of (a) the results of operations for
the three and six month periods ended June 30, 2009 and 2008, (b) the financial
position at June 30, 2009 and December 31, 2008, and (c) cash flows for the six
month periods ended June 30, 2009 and 2008, have been made.
The
unaudited financial statements and notes are presented as permitted by Form
10-Q. Accordingly, certain information and note disclosures normally included in
the financial statements prepared in accordance with accounting principles
generally accepted in the United States of America have been omitted although
the Company generally believes that the disclosures are adequate to ensure that
the information presented is not misleading. The accompanying financial
statements and notes should be read in conjunction with the audited financial
statements and notes of the Company for the fiscal year ended December 31, 2008
included in the Company’s Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 31, 2009 and the Company’s quarterly report
filed with the securities and Exchange Commission on May 20,
2009. The results of operations for the three and six month periods
ended June 30, 2009 are not necessarily indicative of the results that may be
expected for any future quarters or for the entire year ending December 31,
2009.
The
significant accounting policies followed are:
Use of
estimates -
The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.
7
Dais
Analytic Corporation
Notes
to Financial Statements
Three
and Six Months Ended June 30, 2009
(Unaudited)
3. Significant
Accounting Policies (continued)
Loan and
stock issuance costs - Direct loan costs
incurred with the issuance of notes payable are deferred and amortized to
interest expense over the life of the related notes payable. For the
three months ended June 30, 2009 and 2008, the Company incurred amortization
from direct loan costs of $0 and $28,888, respectively. For the six
months ended June 30, 2009 and 2008, the Company incurred amortization from
direct loan costs of $1,004 and $52,742, respectively.
Stock
issuance costs are recorded as a reduction of the related proceeds through a
charge to stockholders’ equity.
Inventory - Inventory consists of
raw materials and is stated at the lower of cost, determined by first-in,
first-out method, or market. Market is determined based on the net
realizable value, with appropriate consideration given to obsolescence,
excessive levels, deterioration and other factors.
Revenue
recognition - Generally, the Company recognizes revenue for its products
upon shipment to customers, provided no significant obligations remain and
collection is probable. Our ConsERV™ product typically carries a warranty of two
years for all parts contained therein with the exception of the energy recovery
ventilator core which typically carries a 10 year warranty. The warranty
includes replacement of defective parts. A warranty reserve is recorded for
estimated costs associated with potential warranty expenses on previous sales.
Warranty cost has been immaterial to our overall operations. Revenue derived
from the sale of licenses is deferred and recognized as revenue on a
straight-line basis over the life of the license, or until the license
arrangement is terminated. The Company recognized revenue of $21,035
and $42,072 from license agreements for each of the three and six month periods
ended June 30, 2009 and 2008, respectively.
Employee
stock options - In December 2004, the Financial Accounting Standards
Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 123
(Revised 2004), “Share-Based Payment” (SFAS 123R). SFAS 123R requires all
share-based payments to employees, including grants of employee stock options,
to be recognized as compensation expense in the financial statements based on
their fair values. That expense will be recognized over the period during which
an employee is required to provide services in exchange for the award, known as
the requisite service period (usually the vesting period).
The value
of each grant under SFAS 123(R) is estimated at the grant date using the
Black-Scholes option model with the following assumptions for options granted
during the six month periods ended June 30, 2009 and 2008:
Six
Months Ended
June
30, 2009
|
Six
Months Ended
June
30, 2008
|
|||||||
Dividend
rate
|
0 | % | 0 | % | ||||
Risk
free interest rate
|
1.65% – 3.21 | % | 2.64% - 3.98 | % | ||||
Expected
term
|
5 –
10 years
|
5 –
10 years
|
||||||
Expected
volatility
|
92% – 105 | % | 80% – 114 | % |
The basis
for the above assumptions are as follows: the dividend rate is based
upon the Company’s history of dividends; the risk-free interest rate for periods
within the contractual life of the option is based on the U.S. Treasury yield
curve in effect at the time of grant; the expected term was calculated based on
the Company’s historical pattern of options granted and the period of time they
are expected to be outstanding; and expected volatility was calculated by review
of a peer company’s historical activity.
SFAS No.
123R requires forfeitures to be estimated at the time of grant and revised, if
necessary, in subsequent periods if actual forfeitures differ from those
estimates. Based on historical experience of forfeitures, the Company
estimated forfeitures at zero percent for the six months ended June 30, 2009 and
2008 and incorporated this rate in the estimated fair value of employee option
grants during 2009 and 2008.
8
Dais Analytic
Corporation
Notes to Financial
Statements
Three and Six Months Ended June 30,
2009
(Unaudited)
3. Significant
Accounting Policies (continued)
Financial
instruments – In September
2006, the Financial Accounting Standards Board (FASB) issued Statement of
Financial Accounting Standards (SFAS) No. 157 “Fair Value Measurements” (SFAS
157). SFAS 157 introduces a framework for measuring fair value and expands
required disclosure about fair value measurements of assets and liabilities.
SFAS 157 for financial assets and liabilities is effective for fiscal years
beginning after November 15, 2007. The Company adopted the standard for those
financial assets and liabilities as of the 2008 fiscal year and the impact of
adoption was not significant. SFAS 157 defines fair value as the exchange price
that would be received for an asset or paid to transfer a liability (an exit
price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date.
SFAS 157 also establishes a fair value hierarchy, which requires an entity to
maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. The standard describes three levels of inputs
that may be used to measure fair value:
|
·
|
Level 1—Quoted prices in active
markets for identical assets or
liabilities.
|
|
·
|
Level 2—Inputs other than quoted
prices included within Level 1 that are either directly or indirectly
observable.
|
|
·
|
Level 3—Unobservable inputs that
are supported by little or no market activity, therefore requiring an
entity to develop its own assumptions about the assumptions that market
participants would use in
pricing.
|
Fair value estimates discussed herein
are based upon certain market assumptions and pertinent information available to
management as of June 30, 2009. The respective carrying value of
certain on-balance-sheet financial instruments approximated their fair values
due to the short-term nature of these instruments. These financial
instruments include accounts receivable, prepaid and other current expenses,
accounts payable, accrued compensation and accrued expenses. The fair value of
the Company’s convertible notes payable is estimated based on current rates that
would be available for debt of similar terms which is not significantly
different from its stated value.
On January 1, 2009, the Company applied
FAS No. 157, “Fair Value Measurements” (FAS 157), for all non-financial assets
and liabilities measured at fair value on a non-recurring basis in accordance
with FASB Staff Position (FSP) FAS 157-2, “Effective Date of FAS 157” (FSP
157-2), which postponed the effective date of FAS 157 for those assets and
liabilities to fiscal years beginning after November 15, 2008, which for the
Company is January 1, 2009. The application of FSP 157-2 did not have an impact
on the Company’s financial position or results of
operations.
Income
taxes – Income taxes are provided for the tax
effects of transactions reported in the financial statements and consist of
taxes currently due plus deferred taxes resulting from temporary differences.
Such temporary differences result from differences in the carrying value of
assets and liabilities for tax and financial reporting purposes. The deferred
tax assets and liabilities represent the future tax consequences of those
differences, which will either be taxable or deductible when the assets and
liabilities are recovered or settled. Valuation allowances are established when
necessary to reduce deferred tax assets to the amount expected to be
realized.
The Company has adopted the provisions
of FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes”. The
Company has not recognized a liability as a result of the implementation of
Interpretation 48. A reconciliation of the beginning and ending amount of
unrecognized tax benefits has not been provided since there is no unrecognized
benefit since the date of adoption. The Company has not recognized interest
expense or penalties as a result of the implementation of Interpretation
48.
Loss
per share – Basic loss per share is computed by
dividing net loss attributable to common stockholders by the weighted average
common shares outstanding for the period. Diluted loss per share is computed
giving effect to all potentially dilutive common shares. Potentially dilutive
common shares may consist of incremental shares issuable upon the exercise of
stock options and warrants and the conversion of notes payable to common stock.
In periods in which a net loss has been incurred, all potentially dilutive
common shares are
considered antidilutive and thus are excluded from the calculation. At June 30,
2009 and 2008, the Company had 42,535,122 and 41,247,638 potentially dilutive
common shares, respectively, which were not included in the computation of loss
per share because
the effect would have been antidilutive. No shares potentially issuable to
satisfy the in-the-money amount of our convertible notes payable have been
included in the computation of diluted loss per share as the conversion options
were not in-the-money.
9
Recent
accounting pronouncements
In June
2009, the Financial Accounting Standards Board (FASB) issued SFAS No. 168,
“The FASB Accounting Standards Codification and the Hierarchy of Generally
Accepted Accounting Principles—a replacement of FASB Statement No. 162,”
(SFAS 168). SFAS 168 replaces SFAS No. 162, “The Hierarchy of Generally
Accepted Accounting Principles,” and establishes the FASB Accounting Standards
Codification (Codification) as the source of authoritative accounting principles
recognized by the FASB to be applied by nongovernmental entities in the
preparation of financial statements in conformity with GAAP. Rules and
interpretive releases of the Securities and Exchange Commission (SEC) under
authority of federal securities laws are also sources of authoritative GAAP for
SEC registrants. The FASB will no longer issue new standards in the form of
Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts;
instead the FASB will issue Accounting Standards Updates. Accounting Standards
Updates will not be authoritative in their own right as they will only serve to
update the Codification. The issuance of SFAS 168 and the Codification does not
change GAAP. SFAS 168 becomes effective for the Company for the period ending
September 30, 2009. The adoption of SFAS 168 will not have an impact on the
financial statements.
In June
2009, the FASB issued SFAS No. 167, “Amendments to FASB Interpretation
No. 46(R),” (SFAS 167). SFAS 167 amends FASB Interpretation No. 46
(Revised December 2003), “Consolidation of Variable Interest Entities—an
interpretation of ARB No. 51,” (FIN 46(R)) to require an enterprise to
perform an analysis to determine whether the enterprise’s variable interest or
interests give it a controlling financial interest in a variable interest
entity; to require ongoing reassessments of whether an enterprise is the primary
beneficiary of a variable interest entity; to eliminate the quantitative
approach previously required for determining the primary beneficiary of a
variable interest entity; to add an additional reconsideration event for
determining whether an entity is a variable interest entity when any changes in
facts and circumstances occur such that holders of the equity investment at
risk, as a group, lose the power from voting rights or similar rights of those
investments to direct the activities of the entity that most significantly
impact the entity’s economic performance; and to require enhanced disclosures
that will provide users of financial statements with more transparent
information about an enterprise’s involvement in a variable interest entity.
SFAS 167 becomes effective for the Company on January 1, 2010. Management
is currently evaluating the potential impact of SFAS 167 on the financial
statements.
Other recent accounting pronouncements
issued by FASB (including EITF), the AICPA and the SEC did not or are not
believed by management to have a material impact on the Company’s present or
future financial statements.
10
Dais Analytic
Corporation
Notes to Financial
Statements
Three and Six Months Ended June 30,
2009
(Unaudited)
4. Notes
Payable
Notes payable consist of the following
at June 30, 2009:
Convertible notes payable;
interest at 9%; maturing from December 2008 to October
2009, collateralized by the Company’s patents and patent
applications
|
$
|
2,025,000
|
||
Notes payable to a related party;
non-interest bearing; due on demand;
unsecured
|
62,524
|
|||
Current portion of notes
payable
|
$
|
2,087,524
|
Convertible Notes
Payable.
During December 2007 and January 2008,
the Company issued convertible promissory notes (the “Convertible Notes”) and
warrants to purchase common stock in exchange for proceeds totaling
$2,950,000. The Convertible Notes bear interest at 9% per annum and
have stated maturity dates from December 2008 to January 2009. The
Convertible Notes are repayable in cash or convertible into shares of the
Company’s stock at a rate of one share per $0.20 of outstanding principle and
interest. Warrants to purchase 14,750,000 shares of the Company’s
common stock accompanying the Convertible Notes are subject to certain
limitations, exercisable at $0.25 per share, vest immediately, and expire
between December 2012 and January 2013.
The Convertible Notes contain an
embedded conversion feature. The Company accounted for this
conversion feature and detachable warrants in accordance with EITF Issue No.
98-5, “Accounting for Securities with Beneficial Conversion Feature or
Contingently Adjustable Conversion Ratio,” and EITF Issue No. 00-27,
“Application of Issue No. 98-5 to Certain Convertible
Instruments.” In accordance with these standards, the Company
allocated the proceeds from issuance of the convertible notes to the beneficial
conversion feature and the warrants based on their relative fair
values. The Company considered EITF No. 00-19 and concluded that the
warrants should be recorded as a component of permanent
equity.
To recognize the fair value of the
warrants, the Company discounted the notes and increased additional paid in
capital. The fair value of the beneficial conversion feature of
$1,383,437 and discount related to the warrants of $1,566,563 were amortized
over the term of the Convertible Notes. For the three months ended
June 30, 2009 and 2008, the Company recognized interest expense from the
amortization of the beneficial conversion feature and discount of $0 and
$735,479, respectively. For the six months ended June 30, 2009 and
2008, the Company recognized interest expense from the amortization of the
beneficial conversion feature and discount of $30,136 and $1,439,452,
respectively.
The following table presents a
reconciliation of the proceeds received from the financing to the carrying value
of the Convertible Notes:
Principal balance of convertible
notes
|
$
|
2,950,000
|
||
Relative fair value of the
warrants
|
(1,566,563
|
)
|
||
Beneficial conversion
feature
|
(1,383,437)
|
|||
Amortization of the
discount
|
1,566,563
|
|||
Amortization of the
beneficial conversion
feature
|
1,383,437
|
|||
Conversion of notes payable
into common stock
|
(925,000)
|
|||
Carrying value at June 30,
2009
|
$
|
2,025,000
|
Between
December 11, 2008 and January 21, 2009, all amounts due under the Convertible
Notes matured and became due and payable in full. The Company has not
repaid any of the amounts due under the respective Convertible Notes. The
Company is currently proposing that holders of matured Convertible Notes either
(i) convert their notes into shares at this time in exchange for additional
warrants or (ii) extend the maturity of the Convertible Notes and continue to
accrue interest. In December 2008 three investors extended the term
of their Convertible Notes and in the six month period ending June 30, 2009 five
investors extended the term of their Convertible Notes. The total face value of
these Convertible Notes was $575,000 of which $475,000 in face value was
extended to September of 2009 and the remainder to October of
2009. In addition, during the six months ended June 30, 2009 four
investors converted the principal balance of $925,000 plus accrued interest of
$100,930 on their Convertible Notes into 5,129,648 shares of common
stock. These investors also received an additional 1,540,125
warrants, exercisable immediately at $0.25 per share and valued at $110,117,
which was recorded as interest expense during the six months ended June 30,
2009.
11
Four
investors holding Convertible Notes with an aggregate outstanding principal
balance of approximately $450,000 at December 31, 2008 had notified the Company
that they were asserting their rights to receive payment of the principal and
interest pursuant to the terms of the Convertible Notes. In June of 2009,
three of these investors, holding an aggregate principal note balance of
$250,000, agreed to extend the term of their Convertible Notes to September 2009
in exchange for Company entering into a confession of judgment. Under that
agreement, the three investors have the right, should the Company fail to pay
all principal and interest due pursuant to their Convertible Notes on or before
September 11, 2009, to file the confession of judgment with the court and seek
to secure a judgment against the Company in the amount of all principal and
interest due under their Convertible Notes together with the reasonable cost and
expense of collection. The total number of investors extending their Convertible
Notes and the face value of said Convertible Notes, as stated in the previous
paragraph, is inclusive of these three investors and the aggregate face value of
their Convertible Notes. In July of 2009, the fourth investor, who had
previously provided notice and holds a Convertible Note in the principal amount
of $200,000, agreed to extend the Convertible Note to September
2009. . As of June 30, 2009, $2,025,000 of convertible
notes were outstanding, of which $575,000 have been extended to
September/October 2009 with the remaining notes due and payable in
full.
Accrued
interest on the notes was $276,191 and $268,453 at June 30, 2009 and December
31, 2008, respectively.
12
Dais Analytic
Corporation
Notes to Financial
Statements
Three and Six Months Ended June 30,
2009
(Unaudited)
5. Related
Party Transactions
The Company rents a building that is
owned by two stockholders of the Company, one of which is the Chief Executive
Officer. Base rent expense is $3,800 per month. The
Company recognized rent expense of $12,198 and $24,396 in each of the three and
six month periods ended June 30, 2009 and 2008, respectively. These
amounts are not necessarily indicative of the amounts that would have been
incurred had comparable transactions been entered into with independent parties.
However, at the time the Company entered into the lease agreement, based on then
current economic conditions, the real estate market, and the Company’s
prospects, the Company believed that the lease was on terms no less favorable to
the Company than could generally be obtained from independent
parties.
The Company also has accrued
compensation due to the Chief Executive Officer and one other employee for
deferred salaries earned and unpaid as of June 30, 2009 of
$1,245,189.
On May 21, 2009, to evidence a loan,
Company issued its Chief Executive Officer a promissory note in the principal
amount of $51,900. The note is unsecured and bears a simple interest rate of 7%
per annum. The principal amount plus all accrued interest is to be paid in full
to the holder no later than July 31, 2009. This note was paid in full
prior to July 31, 2009.
On June 10, 2009, to evidence a loan,
the Company issued a promissory note in the principal amount of $10,000 to Ethos
Business Ventures, an entity in which its Chief Executive Officer holds a
position. The note is unsecured and bears a simple
interest rate of 7% per annum. The principal amount plus all interest accrued is
to be paid in full to the holder no later than July 31,
2009. This note was paid in full prior to July 31,
2009.
6. Stock
Options and Warrants
At June 30, 2009, the Company has a
stock option plan (the “2000 Plan”) that provides for the granting of options to
qualified employees of the Company, independent contractors, consultants,
directors and other individuals. As of June 30, 2009, the
Company’s Board of
Directors approved and made available 11,093,882 shares of common stock to be
issued pursuant to the
2000 plan. The 2000
Plan permits grants of options of common shares authorized and approved by the
Company’s Board of Directors for issuance prior to enactment of the 2000
Plan.
The following summarizes the information
relating to outstanding stock options activity with employees during the
2009:
Shares
|
Weighted Average
Exercise
Price
|
Weighted Average
Remaining
Contractual Term
in years)
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Shares under option at
December 31,
2008
|
8,606,556 | $ | 0.27 | |||||||||||||
Granted
|
- | - | ||||||||||||||
Exercised
|
- | - | ||||||||||||||
Forfeited or
expired
|
(172,732 | ) | $ | 0.32 | ||||||||||||
Outstanding at June 30,
2009
|
8,433,824 | $ | 0.25 | 7.07 | $ | 95,984 | ||||||||||
Exercisable at June 30,
2009
|
8,081,768 | $ | 0.25 | 6.73 | $ | 95,984 |
13
Dais Analytic
Corporation
Notes to Financial
Statements
Three and Six Months Ended June 30,
2009
(Unaudited)
Stock compensation expense was $69,591
and $148,306 for the three and six month periods ending June 30, 2009,
respectively. Stock compensation expense was $74,448 and
$946,202 for the three and six months ended June
30, 2008, respectively.
6. Stock
Options and Warrants (continued)
As of June 30, 2009, there was
$307,093 of unrecognized employee stock-based compensation expense related
to non vested stock options. This expense will be recognized over a
weighted average period of .92 years.
The following table represents our non
vested share-based payment activity for the six months ended June 30,
2009:
Weighted
Average
|
||||||||
Number of
|
Grant Date
|
|||||||
Options
|
Fair Value
|
|||||||
Nonvested options - December 31,
2008
|
1,276,563
|
$ |
0.37
|
|||||
|
||||||||
Granted
|
-
|
|||||||
Vested
|
(894,175
|
)
|
||||||
Forfeited
|
(30,333)
|
|||||||
Nonvested options – June 30,
2009
|
352,055
|
$ |
0.22
|
Warrants and
Options
At June 30, 2009, the Company had
outstanding warrants and options to purchase the Company’s common stock which
were issued in connection with multiple financing arrangements, consulting
agreements and employment agreements. Information relating to these
warrants and options is summarized as follows:
Warrants
|
Remaining
Number Outstanding
|
Weighted Average
Remaining
Life
(Years)
|
Weighted Average
Exercise
Price
|
|||||||||
Warrants-Daily
Financing
|
197,055 | 2.49 | $ | 0.55 | ||||||||
Warrants-Additional
Financing
|
428,637 | 3.21 | $ | 0.40 | ||||||||
Warrants-Robb
Trust Note
|
50,000 | 2.93 | $ | 0.55 | ||||||||
Warrants-Financing
|
14,750,000 | 1.83 | $ | 0.25 | ||||||||
Warrants-Placement
Agent Warrants
|
1,792,308 | 3.67 | $ | 0.25 | ||||||||
Warrants-Tangredi
|
3,000,000 | 3.76 | $ | 0.36 | ||||||||
Warrants-Ehrenberg
|
250,000 | 4.10 | $ | 0.30 | ||||||||
Warrants-Consulting
Agreement
|
250,000 | 4.84 | $ | 0.26 | ||||||||
Warrants-Note
Conversions
|
1,540,125 | 4.73 | $ | 0.25 | ||||||||
Warrants-Stock
Purchases 2009
|
636,439 | 4.84 | $ | 0.26 | ||||||||
Options-Mandelbaum
|
200,000 | 4.84 | $ | 0.19 | ||||||||
Total
|
23,094,564 |
7. Commitments
and Contingencies
The Company has employment agreements
with some of its key employees and executives. These agreements
provide for minimum levels of compensation during current and future
years. In addition, these agreements call for grants of stock options
and for payments upon termination of the agreements.
14
Between December 11, 2008 and January
21, 2009, all amounts due under the Convertible Notes matured and became due and
payable in full. The Company has not repaid any of the amounts due
under the respective Convertible Notes. In 2009 four
investors with outstanding
principal balances of approximately $450,000 in the aggregate, notified the Company that they were
asserting their rights to receive payment of the principal and interest pursuant
to the terms of the Convertible Notes. In June of 2009, three of
these investors, holding an aggregate principal note balance of $250,000, agreed
to extend the term of their Convertible Notes to September 2009 in exchange for
Company entering into a confession of judgment. Under that agreement, the three
investors have the right, should the Company fail to pay all principal and
interest due pursuant to their Convertible Notes on or before September 11,
2009, to file the confession of judgment with the court and seek to secure a
judgment against the Company in the amount of all principal and interest due
under their Convertible Notes together with the reasonable cost and expense of
collection. In July of
2009, the fourth investor, who had given notice and holds a Convertible Note in
the principal amount of $200,000, agreed to extend the Convertible Note to
September 2009. The Company is
currently proposing that the holder of matured Convertible Notes either (i)
convert their notes into shares at this time in exchange for additional warrants
or (ii) extend the maturity of the Convertible Notes and continue to accrue
interest. Certain investors have extended the maturity dates of their
notes or converted their notes to common stock.
The Company entered into an agreement
with the holders of the Convertible Notes to file a registration statement
within a defined timeframe. The Company will incur penalties and
damages of up to approximately $236,000 if it does not file and keep the
registration statement effective pursuant to the terms of this
agreement. As of June 30, 2009, the Company has recorded a liability
of $41,000 related to this agreement.
In June 2008, the Company hired a
consultant to assist in evaluating possible environmental credit
opportunities. A portion of any such credits obtained, or revenue
generated from the sale thereof, is payable by the Company to the
consultant.
8. Subsequent
Events
During
July 2009, the Company issued a $300,000 note payable to an
investor. The note bears 7% interest per annum, however, the
repayment terms have yet to be finalized.
During
July 2009, an investor holding a Convertible Note in the principal amount of
$200,000 agreed to extend the term of his Convertible Note to September
2009.
In August of 2009, an investor elected
to convert his Convertible Note and the related accrued interest in the amount
of $85,541 into 427,706 shares of the Company’s common stock. The
investor also received an additional warrant to purchase up to 124,875 shares of Company’s common stock, at an
exercise price of $.25 per share in consideration for converting the Convertible
Note.
In August
2009 the Company entered an agreement describing the terms and conditions under
which a Consultant serves as the Chief Financial Officer. As payment
for said services, Company has issued the Consultant an option to purchase
200,000 shares of the Company’s common stock and will make a cash payment to
Consultant of $3,333 per month. The 200,000 options shall be
exercisable at a price of $.19 per share for a period of 10 years from the
option grant date and will vest as follows: (i) 50,000 options upon the three
month anniversary of the option grant date, and (ii) 50,000 options shall vest
every three (3) months thereafter until the entire number of options is
vested.
15
ITEM
2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATION
The following discussion and analysis of
our financial condition and results of operations should be read in conjunction
with our financial statements and the notes thereto included elsewhere in this
quarterly report on Form 10-Q and in our Form 10K filed with the Securities and
Exchange Commission on March 31, 2009.
THIS FILING, INCLUDING BUT NOT
LIMITED TO “MANAGEMENT’S DISCUSSION AND ANALYSIS”, CONTAINS FORWARD-LOOKING
STATEMENTS. THE WORDS “ANTICIPATED,” “BELIEVE,” “EXPECT,” “PLAN,” “INTEND,”
“SEEK,” “ESTIMATE,” “PROJECT,” “WILL,” “COULD,” “MAY,” AND SIMILAR EXPRESSIONS
ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS INCLUDE,
AMONG OTHERS, INFORMATION REGARDING FUTURE OPERATIONS, FUTURE CAPITAL
EXPENDITURES, AND FUTURE NET CASH FLOW. SUCH STATEMENTS REFLECT THE COMPANY’S
CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND FINANCIAL PERFORMANCE AND
INVOLVE RISKS AND UNCERTAINTIES, INCLUDING, WITHOUT LIMITATION, GENERAL ECONOMIC
AND BUSINESS CONDITIONS, CHANGES IN FOREIGN, POLITICAL, SOCIAL, AND ECONOMIC
CONDITIONS, REGULATORY INITIATIVES AND COMPLIANCE WITH GOVERNMENTAL REGULATIONS,
THE ABILITY TO ACHIEVE FURTHER MARKET PENETRATION AND ADDITIONAL CUSTOMERS, AND
VARIOUS OTHER MATTERS, MANY OF WHICH ARE BEYOND THE COMPANY’S CONTROL. OUR
ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN
THESE FORWARD- LOOKING STATEMENTS AS A RESULT OF SEVERAL FACTORS, INCLUDING THE
RISKS FACED BY US AS DESCRIBED BELOW AND ELSEWHERE IN THIS FORM 10-Q AS WELL AS
IN OUR FORM 10-K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 31,
2009. IN LIGHT OF THESE RISKS AND UNCERTAINTIES THERE CAN BE NO ASSURANCE THAT
THE FORWARD-LOOKING STATEMENTS CONTAINED IN THIS FORM 10-Q WILL OCCUR. WE HAVE
NO OBLIGATION TO PUBLICLY UPDATE OR REVISE THESE FORWARD-LOOKING STATEMENTS TO
REFLECT NEW INFORMATION, FUTURE EVENTS, OR OTHERWISE ,EXCEPT AS REQUIRED BY
FEDERAL SECURITIES LAWS AND WE CAUTION YOU NOT TO PLACE UNDUE RELIANCE ON THESE
FORWARD-LOOKING STATEMENTS. WE MAY NOT UPDATE THESE
FORWARD-LOOKING STATEMENTS, EVEN THOUGH OUR SITUATION MAY CHANGE IN THE
FUTURE.
OVERVIEW
We have
developed and patented a nano-structure polymer technology, which is being
commercialized in products based on the functionality of these materials. We
believe the applications of our technology have promise in a number of diverse
market segments and products.
The
initial product focus of the Company is ConsERV, an energy recovery
ventilator. Our primary focus is to expand our marketing and sales of
our ConsERV™ product.
We also
have new product applications in various developmental stages. We
believe that three of these product applications, including an advanced air
conditioning system which is projected to use less energy and emits fewer
emissions than current HVAC equipment, a sea-water desalination product and an
electrical energy storage device, can be brought to market in the foreseeable
future if we receive adequate capital funding.
REVENUES
We
generate our revenues primarily from the sale of our ConsERV™ products in
residential and commercial HVAC markets. Sales channels for our
ConsERV™ products include OEMs, distributors, retailers, and
consumers. We also occasionally license our technology to strategic
partners and sell various prototypes of other product applications that use our
polymer technology.
Our
revenue growth is dependent on continued sales from (i) more seasoned
independent sales representatives, (ii) a greater number of independent sales
representatives (iii) fulfilling the ventilation needs of the growing “energy
consultant” marketplace which work to lower their client’s energy
costs and emissions, and (iv) from the Company’s own ‘customer
direct’ sales activities, all of which focus on the sale of product primarily
into the commercial user marketplace with a growing emphasis on low rise
structures (small commercial buildings, multi-purpose structures, and
residences). In addition, the Company and its independent sales
representative sales force will work to secure orders for ConServ “core only”
sales (i) from HVAC equipment manufacturers, (ii) from distribution firms
servicing the equipment needs of the HVAC installer community, and (iii)
creating license/supply relationships to HVAC or ERV OEMs preferably having a
dominant presence in existing direct related sales channels.
16
COST OF
SALES
Our cost
of sales consists primarily of materials (including freight), direct labor, and
outsourced manufacturing expenses incurred to produce our ConsERV™
products.
We are
dependent on third parties to manufacture the key components needed for our
nano-structured based materials and value added products made with these
materials. Accordingly, a supplier’s failure to supply components in a timely
manner, or to supply components that meet our quality, quantity and cost
requirements or our technical specifications, or the inability to obtain
alternative sources of these components on a timely basis or on terms acceptable
to us, would create delays in production of our products or increase our unit
costs of production. Certain of the components contain proprietary products of
our suppliers, or the processes used by our suppliers to manufacture these
components are proprietary. If we are required to replace any of our
suppliers, while we should be able to obtain comparable components from
alternative suppliers at comparable costs, this would create a delay in
production.
SELLING,
GENERAL AND ADMINISTRATIVE EXPENSES
Our
selling, general and administrative expenses consist primarily of payroll and
related benefits, share-based compensation, professional fees, marketing and
channel support costs, and other infrastructure costs such as insurance,
information technology and occupancy expenses.
Results of
Operations
The following table sets forth, for the
periods indicated, certain data derived from our Statements of Operations and
certain of such data expressed as a percentage of revenues:
Three Months
Ended
|
Six Months
Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Revenues
|
$
|
528,353
|
$
|
284,078
|
$
|
685,706
|
$
|
497,589
|
||||||||
Percentage of
revenues
|
100
|
%
|
100.0
|
%
|
100
|
%
|
100.0
|
%
|
||||||||
Cost of goods
sold
|
$
|
337,574
|
$
|
218,057
|
$
|
444,544
|
$
|
377,990
|
||||||||
Percentage of
revenues
|
63.9
|
%
|
76.8
|
%
|
64.8
|
%
|
76.0
|
%
|
||||||||
Selling, general and
administrative expenses
|
$
|
439,426
|
$
|
502,304
|
$
|
982,798
|
$
|
1,758,403
|
||||||||
Percentage of
revenues
|
83.2
|
%
|
176.8
|
%
|
143.3
|
%
|
353.4
|
%
|
||||||||
Interest
expense
|
$
|
95,353
|
$
|
831,435
|
$
|
251,585
|
$
|
1,690,655
|
||||||||
Percentage of
revenues
|
18.0
|
%
|
292.7
|
%
|
36.7
|
%
|
339.8
|
%
|
||||||||
Net loss
|
$
|
(344,000)
|
$
|
(1,262,192)
|
$
|
(993,184)
|
$
|
(3,313,177)
|
||||||||
Percentage of
revenues
|
(65.1)
|
%
|
(444.3)
|
%
|
(144.8)
|
%
|
(665.9)
|
%
|
17
Summary of Three Months Ended June 30,
2009 Results of Operations
REVENUES:
Total revenues for the
three months ended June 30, 2009 and 2008 were $528,353 and $284,078, respectively, an increase of $244,275 or 86%. The
increase in revenues in the 2009 period is primarily attributable to
the Company increasing the sales price of
the ConsERV products and an increase in the number and magnitude of its sales transactions. The Company also attributes the sales increase to a
realignment of its independent sales representatives, the increase in the number
of such sales representatives and the hiring of an additional internal sales
person and engineer to support its sales staff. During the three
months ended June 30, 2009 and 2008, four and two customers accounted for
approximately 69% and 73% of revenues, respectively.
COST OF GOODS SOLD:
Cost of goods sold
increased $119,517 to $337,574 and represented 63.9% of revenues, for the three months ended June 30, 2009 compared to
$218,057 or 76.8% of revenues for the three months ended June 30,
2008. The increase in cost of goods sold
during 2009 is primarily due to the increase in sales. The decrease in cost of goods sold as a percentage of
revenue in 2009 is
primarily attributable to a decrease in the cost of materials due to
the implementation of improvements to the production process of certain product
components and outsourcing
some of the production in order to maximize the gross margin.
SELLING, GENERAL AND
ADMINISTRATIVE EXPENSES: Selling, general and administrative
expenses of $439,426 for the three months ended June 30, 2009 decreased
$62,878 from $502,304 in the same period of 2008 or 12.5%. This decrease
is primarily due to a decrease of $66,900 in payroll expenses due, in part, to a
salary adjustment initiated in April of 2009 and a decrease of 11,900 in air
travel as the prior year contained additional
travel to establish new customers and investigating potential
vendors. These decreases were partially offset by an increase in insurance costs of
$19,600 which is mainly due
to an increase in the Company’s Director’s and Officer’s insurance policy as the
Company is now a publicly reporting entity.
INTEREST EXPENSE:
Interest expense
was $95,353 for the three months ended June
30, 2009 compared to $831,435 for the same period of 2008, a decrease of
$736,082. During the three months ended June 30, 2009, interest
expense was related to
convertible notes issued from December 2007 to January 2008 of approximately
$46,900 and approximately $46,900 in expense relating to warrants issued to
induce conversion of principal and interest accrued on two convertible notes
having a principal value of $250,000. Interest expense for the three
months ended June 30, 2008 relates primarily to amortization of the beneficial
conversion feature and discount on outstanding notes payable. The decrease in
interest expense in 2009
is due to fact that the
beneficial conversion feature and discount on the notes payable was fully
amortized at April 1, 2009.
NET LOSS:
Net loss for the three
months ended June 30, 2009 decreased by $918,192 to $344,000 from $1,262,192 for the
three months ended June 30, 2008. The decrease
in net loss is primarily due to the increase in gross margin, coupled with the decreases in selling, general and administrative
expenses and interest expense as discussed above.
Summary of Six Months Ended June 30,
2009 Results of Operations
REVENUES:
Total revenues for the six
months ended June 30, 2009 and 2008 were $685,706 and $497,589, respectively, an
increase of $188,117 or 37.8%. The increase in revenues in 2009 is
primarily attributable to the Company increasing the sales price of the ConsERV
products and increasing the number and magnitude of its sales transactions. The Company also attributes the increase in sales to its
realignment of its independent sales representatives, the increase in the number
of such sales representatives and hiring of an additional internal sales person and
engineer to support its sales staff. During the six months ended June
30, 2009 and 2008, four and two customers accounted for approximately 68% and
73% of revenues, respectively.
COST OF GOODS SOLD:
Cost of goods sold
increased $66,554 to $444,544 and represented 64.8% of revenues, for the six
months ended June 30, 2009 compared to $377,990 or 76.0% of revenues for the six
months ended June 30, 2008. The increase in cost of goods sold in 2009 is primarily a factor of the increase in sales. The decrease in cost of goods sold as a percentage of
revenue in 2009 is
primarily attributable to a decrease in the cost of materials due to
the implementation of improvements to the production process of certain product
components and outsourcing
some of the production in order to maximize the gross margin.
SELLING, GENERAL AND
ADMINISTRATIVE EXPENSES: Selling, general and administrative
expenses of $982,798 for the six months ended June 30, 2009
decreased $775,605 from $1,758,403 in the same period of
2008 or 44.1%. This decrease is primarily due
to a decrease in stock
based compensation awards of approximately $798,200 as there were no awards given during
2009 and the Company granted a large stock compensation award during
2008. Also, there was a decrease in payroll expenses of
approximately $20,100, due
to a companywide temporary reduction in salaries. These decreases
were partially offset by
an increase in insurance costs of
approximately $17,900 due
to the higher cost of Director’s and Officer’s Liability Insurance and during the later part of 2008 and an
increase of approximately $25,600 in legal and accounting fees due to increased year-end audit
costs.
18
INTEREST EXPENSE:
Interest expense was
$251,585 for the six months ended June 30, 2009 compared to $1,690,655 for the
same period of 2008, a decrease of $1,439,070. During the six months
ended June 30, 2009, interest expense was related to convertible notes issued
from December 2007 to January 2008, including approximately $108,900 of interest
payable to the convertible
note holders and
approximately $110,100 in expense relating to warrants
issued to induce conversion of principal and interest accrued on four
convertible notes having a principal value of $925,000. Interest expense
for the six months ended June 30, 2008 relates primarily to amortization of the
beneficial conversion feature discount on outstanding notes payable. The
decrease in interest expense is due to fact that the beneficial conversion
feature and discount on the notes payable became fully amortized in January 2009.
NET LOSS:
Net loss for the six months
ended June 30, 2009 decreased by $2,319,993 to $993,184 from $3,313,177 for the six
months ended June 30, 2008. The decrease in the
net loss is primarily due to the increase in gross margin in 2009, coupled with the decreases in selling, general and administrative
expenses and interest expense as discussed above.
19
Liquidity and Capital
Resources
The Company finances its operations
primarily through sales of its ConsERV™ products, sales of its common stock, the
issuance of convertible promissory notes and license
agreements.
Our historical revenues have not been
sufficient to sustain our operations. We have not achieved
profitability in any year since inception and we expect to continue to incur net
losses and negative cash flow from operations until we can produce sufficient
revenues to cover our costs, which is not expected for several
years. Furthermore, even if we achieve our projection of selling a
greater number of ConsERV™ units, we anticipate that we will continue to incur
losses until we can cost-effectively produce and sell our products to a wider
market. Our profitability will require the successful
commercialization of our ConsERV™ products and any future products we develop.
No assurances can be given when this will occur.
In December 2007 and January 2008 we issued $2,950,000
of one year Convertible Notes. At June 30, 2009, we had outstanding debt from
these 9% convertible secured promissory
notes of $ 2,025,000 plus related interest. The notes matured commencing in
December 2008 through January 2009. We did not have adequate funds to repay the
notes upon maturity. The notes are secured by all of the Company’s
patents and the majority of the Company’s patent applications. The
Company is currently proposing that holders of matured Convertible Notes either
(i) convert their notes into shares at this time in exchange for additional
warrants or (ii) extend the maturity of the Convertible Notes and continue to
accrue interest. In December 2008 three investors extended the term
of their Convertible Notes and in the six month period ending June 30, 2009,
five investors extended the term of their Convertible Notes. The total face
value of these Convertible Notes was $575,000 of which $475,000 in face value
was extended to September of 2009 and the remainder to October of
2009. In addition, during the six months ended June 30, 2009 four
investors converted the principal balance of $925,000 plus accrued interest of
$100,930 on their Convertible Notes into 5,129,648 shares of common
stock. For agreeing to convert their Convertible Notes, these
investors also received an additional 1,540,125 warrants, exercisable
immediately at $0.25 per share and valued at $110,117, which was recorded as
interest expense during the six months ended June 30,
2009.
Four
investors holding Convertible Notes with an aggregate outstanding principal
balance of approximately $450,000 at December 31, 2008 had notified the Company
that they were asserting their rights to receive payment of the principal and
interest pursuant to the terms of the Convertible Notes. In June of 2009,
three of these investors, holding an aggregate principal note balance of
$250,000, agreed to extend the term of their Convertible Notes to September
2009. The Company delivered to these investors a confession of
judgment to be filed with the court if the Company fails to pay all principal
and interest due pursuant to their Convertible Notes on or before September 11,
2009. If the confession of judgment is filed, these investors may
seek to secure a judgment against the Company in the amount of all principal and
interest due under their Convertible Notes together with the reasonable cost and
expense of collection. The total number of investors extending their Convertible
Notes and the face value of said Convertible Notes, as stated in the previous
paragraph, is inclusive of these three investors and the aggregate face value of
their Convertible Notes. In July of 2009, the fourth investor, who had
previously provided notice and holds a Convertible Note in the principal amount
of $200,000, agreed to extend the Convertible Note to September 2009. As of June 30, 2009,
$2,025,000 of convertible notes were outstanding, of which $575,000 have been
extended to September/October 2009 with the remaining notes due and payable in
full.
The Company may not be able to secure
additional financing to repay the notes on acceptable terms, if at all, and we
are currently unable to pay the notes that have matured. As an alternative,
management may attempt to renegotiate the repayment terms of the notes and seek
extension of the maturity dates. There is no guarantee that any
re-negotiated terms we may be able to secure would be favorable to the Company.
Unfavorable terms, in either a financing transaction or debt renegotiation,
would adversely impact our business, financial condition and/or results of
operations. In the event (i) we are unable to secure additional financing
sufficient to pay the notes, (ii) the notes are not converted into shares of our
common stock pursuant to their terms, or (iii) we are not able to negotiate
extensions to the maturity dates of the notes, note holders will have the option
to foreclose on all of our patents and those patent applications securing the
notes, which would likely result in the failure of our
business.
Any future financing may result in
substantial dilution to existing shareholders, and future debt financing, if
available, may include restrictive covenants or may require us to grant a lender
a security interest in any of our assets not already subject to an existing
security interest. To the extent that we attempt to raise additional funds
through third party collaborations and/or licensing arrangements, we may be
required to relinquish some rights to our technologies or products currently in
various stages of development, or grant licenses or other rights on terms that
are not favorable to us. Any failure by us to timely procure additional
financing or investment adequate to fund our ongoing operations, including
planned product development initiatives, clinical studies and commercialization
efforts, will have material adverse consequences on our financial condition,
results of operations and cash flows.
20
We will be dependent upon our existing
cash of $34,888 at June 30,
2009, product
sales, a recent loan of
$300,000 (received in July 2009) from one of our investors and additional debt and equity issuances
to finance our operations through the next 12 months. We need to raise additional capital of
approximately $13 to $18 million, net of offering costs, during the next nine to
twelve months, the proceeds of which will be used to pay down existing debt,
secure new patents for innovative applications of our core technology, purchase
equipment, and fund our working capital requirements through June 30,
2010. We currently have no commitments for any such
funds.
Our ability to continue as a going
concern is highly dependent on our ability to obtain additional sources of cash
flow sufficient to fund our working capital requirements, including repayment of
our debt obligations. We intend to finance our operations, including the
repayment of notes payable, primarily through private sales of debt and equity
securities, licensing revenues, and sales of non-core uses of our
technology. Any failure by us to timely secure the cash flow adequate to
fund our debt obligations and ongoing operations will have a materially adverse
consequence on our financial condition, results of operations and cash
flows.
Statement of Cash
Flows
The
following table sets forth, for the periods indicated, selected cash flow
information:
|
Six
Months Ended June 30,
|
||||||||
2009
|
2008
|
||||||||
Cash
flows used in operating activities
|
$ |
|
(369,626
|
) | $ |
|
(933,593
|
) | |
Cash
flows used in investing activities
|
(15,253
|
) |
(14,647
|
) | |||||
Cash
flows provided by financing activities
|
392,900
|
1,366,000
|
|||||||
Net
increase in cash and cash equivalents
|
$ |
|
8,021
|
$ |
|
417,760
|
During the six months ended June 30,
2009, cash used in operating activities consisted of our net loss of $993,184,
less non-cash adjustments such as issuance of stock options and warrants for
services and debt conversions totaling $373,807 and also adjusted for cash
provided by increases in accounts payable and accrued expenses of $277,669, as
well as other changes in operating assets and liabilities. Financing
activities provided $392,900 of cash from net proceeds from the issuance of
common stock of $331,000 and $61,900 proceeds from the issuance of a note
payable.
During the six months ended June 30,
2008, the cash flows provided by financing activities was mainly attributable to
the issuance of convertible notes payable and the release of escrow cash related
to the convertible notes payable.
ECONOMY AND
INFLATION
Except as disclosed herein, we have not
experienced any significant cancellation of orders due to the downturn in the
economy and only a small number of customers requested delays in delivery or
production of orders in process. Our management believes that inflation has not
had a material effect on our results of operations.
OFF-BALANCE SHEET
ARRANGEMENTS
We do not have any off balance sheet
arrangements that are reasonably likely to have a current or future effect on
our financial condition, revenues, and results of operations, liquidity or
capital expenditures.
21
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLSOURES ABOUT MARKET
RISK
Not applicable.
ITEM 4T. CONTROLS
AND PROCEDURES
Evaluation
of disclosure controls and procedures
Our Chief Executive Officer and Chief
Financial Officer (collectively the “Certifying Officers”) maintain a system of
disclosure controls and procedures that is designed to provide reasonable
assurance that information, which is required to be disclosed, is accumulated
and communicated to management timely. The Certifying Officers have concluded
that the disclosure controls and procedures are effective at the “reasonable
assurance” level. Under the supervision and with the participation of
management, as of the end of the period covered by this report, the Certifying
Officers evaluated the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e)
under the Exchange Act). Furthermore, the Certifying Officers concluded that our
disclosure controls and procedures in place are designed to ensure that
information required to be disclosed by us in reports that we file or submit
under the Exchange Act is (i) recorded, processed, summarized and reported on a
timely basis in accordance with applicable Commission rules and regulations; and
(ii) accumulated and communicated to our management, including our Certifying
Officers and other persons that perform similar functions, if any, to allow us
to make timely decisions regarding required disclosure in our periodic
filings.
Changes in
Internal Control Over Financial Reporting
No change in the Company’s internal
control over financial reporting occurred during the six months ended June 30,
2009, that materially affected, or is reasonably likely to materially affect,
the Company’s internal control over financial reporting.
Part II — OTHER
INFORMATION
Item 1. Legal
Proceedings
The status of our legal proceedings, as
disclosed in our Annual Report remains unchanged.
The Company is party to lawsuits from
time to time arising in the ordinary course of its businesses. The
Company provides for costs relating to these matters when a loss is probable and
the amount is reasonably estimable. The effect of the outcome of these matters
on the Company's future results of operations cannot be predicted because any
such effect depends on future results of operations and the amount and timing of
the resolution of such matters.
22
Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds
Other
than as disclosed in our Form 8-K, filed with the Securities and Exchange
Commission on July 7, 2009 and 48,000 shares of common stock issued to a
consultant pursuant to an extension of a consulting agreement, Company has
not issued securities during the period pertaining to this Form 10-Q
filing.
Item 3. Defaults
Upon Senior Securities
Other than disclosed in Company’s Form
8-K filings with the Securities and Exchange Commission there have been no
defaults in any material payments during the covered
period.
Item 4. Submission
of Matters to a Vote of Security Holders
During the three months ended June 30,
2009, the Company did not submit any matters to a vote of its security
holders.
Item 5. Other
Information
In August
2009 the Company entered an agreement describing the terms and conditions under
which a Consultant serves as the Chief Financial Officer. As payment
for said services, Company has issued the Consultant an option to purchase
200,000 shares of the Company’s common stock and will make a cash payment to
Consultant of $3,333 per month. The 200,000 options shall be
exercisable at a price of $.19 per share for a period of 10 years from the
option grant date and will vest as follows: (i) 50,000 options upon the three
month anniversary of the option grant date, and (ii) 50,000 options shall vest
every three (3) months thereafter until the entire number of options is
vested.
23
Item 6. Exhibits
No.
|
Item 6 –
Exhibits
|
|
3.1
|
Certificate of Incorporation of
The Dais Corporation filed April 8, 1993*
|
|
3.2
|
Certificate of Amendment of the
Certificate of Incorporation of The Dais Corporation filed February 21,
1997*
|
|
3.3
|
Certificate of Amendment of the
Certificate of Incorporation of The Dais Corporation filed June 25,
1998*
|
|
3.4
|
Certificate of Amendment of the
Certificate of Incorporation of Dais Analytic Corporation filed December
13, 1999*
|
|
3.5
|
Certificate of Amendment of the
Certificate of Incorporation of Dais Analytic Corporation filed September
26, 2000*
|
|
3.6
|
Certificate of Amendment of the
Certificate of Incorporation of Dais Analytic Corporation filed September
28, 2000*
|
|
3.7
|
Certificate of Amendment of the
Certificate of Incorporation of Dais Analytic Corporation filed August 28,
2007*
|
|
3.8
|
Certificate of Amendment of the
Certificate of Incorporation of Dais Analytic Corporation filed March 20,
2008*
|
|
3.9
|
Bylaws of The Dais
Corporation*
|
|
4.1
|
Form of Non-Qualified Stock Option
Agreement*
|
|
4.2
|
Form of Non-Qualified Option
Agreement*
|
|
4.3
|
Form of Warrant (Daily
Financing)*
|
|
4.4
|
Form of Warrant
(Financing)*
|
|
4.5
|
Form of Warrant (Robb Trust Note
and Additional Financing)*
|
|
4.6
|
Form of Placement Agent Warrant
(Financing)*
|
|
4.7
|
Form of 9% Secured Convertible
Note (Financing)*
|
|
4.8
|
Form of Note (Robb Trust
Note)*
|
|
4.9
|
Form of Amendment to Note (Robb
Trust Note)*
|
|
4.10
|
Form of Warrant (Note
Conversion)**
|
|
4.11
|
Form of Warrant (Gostomski and
Weston)**
|
|
10.1
|
2000 Equity Compensation
Plan*
|
|
10.2
|
Form of Employee Non-Disclosure
and Non-Compete Agreement*
|
|
10.3
|
Amended and Restated Employment
Agreement between Dais Analytic Corporation and Timothy N. Tangredi dated
July 29, 2008*
|
|
10.4
|
Amended and Restated Employment
Agreement between Dais Analytic Corporation and Patricia K. Tangredi dated
July 29, 2008*
|
|
10.5
|
Commercial Lease Agreement between
Ethos Business Venture LLC and Dais Analytic Corporation dated March 18,
2005*
|
|
10.6
|
First Amendment of Lease Agreement
between Ethos Business Venture LLC and Dais Analytic Corporation dated
November 15, 2005*
|
|
10.7
|
Form of Subscription Agreement
(Daily Financing)*
|
|
10.8
|
Form of Subscription Agreement
(Financing)*
|
|
10.9
|
Form of Registration Rights
Agreement (Financing)*
|
|
10.10
|
Form of Secured Patent Agreement
(Financing)*
|
|
10.11
|
Placement Agent Agreement between
Dais Analytic Corporation and Legend Merchant Group, Inc.,
dated October 5, 2007
|
|
10.12
|
Consulting
Agreement between Dais Analytic Corporation and Harold Mandelbaum dated
August 12, 2009
|
|
14.1
|
Code of
Ethics***
|
|
31.1
|
Certification
of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley
Act of 2002
|
|
31.2
|
Certification
of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley
Act of 2002
|
|
32.1
|
Certification
of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
|
32.2
|
Certification
of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
*
|
Incorporated by reference to the
exhibits included with the Registration Statement on Form S-1, File No.
333-152940, as filed August 11, 2008.
|
**
|
Incorporated by reference to the
exhibits included with the Current Report on Form 8-K, as filed March 13,
2009.
|
*** |
Incorporated
by reference to the exhibits included with Annual Report on Form 10-K, as
filed March 31,
2009
|
24
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly
authorized.
DAIS
ANALYTIC CORPORATION
(Registrant)
|
|||
/s/ TIMOTHY N.
TANGREDI
|
Dated:
|
August 14,
2009
|
|
Timothy N.
Tangredi
|
|||
President and Chief Executive
Officer
|
|||
(Principal Executive
Officer)
|
|||
/s/ Harold
Mandelbaum
|
Dated:
|
August
14,
2009
|
|
Harold
Mandelbaum
|
|||
Chief Financial
Officer
|
|||
(Principal Financial and
Accounting Officer)
|
25